Furthermore, breast cancer patients with obesity are less sensitive to anti VEGF treatment and they have increased systemic concentrations of IL-6 and fibroblast growth factor-2 (FGF-2) [126]. The gene discussed is FGF2; the disease is obesity due to melanocortin 4 receptor deficiency.